Tumour-induced osteomalacia (TIO), also known as oncogenic osteomalacia, is a rare paraneoplastic disorder caused by tumours that secrete fibroblast growth factor 23 (FGF23). Owing to the role of FGF23 in renal phosphate handling and vitamin D synthesis, TIO is characterized by decreased renal tubular reabsorption of phosphate, by hypophosphataemia and by low levels of active vitamin D. Chronic hypophosphataemia ultimately results in osteomalacia (that is, inadequate bone mineralization). The diagnosis of TIO is usually suspected when serum phosphate levels are chronically low in the setting of bone pain, fragility fractures and muscle weakness. Locating the offending tumour can be very difficult, as the tumour is often very small and can be anywhere in the body. Surgical removal of the tumour is the only definitive treatment. When the tumour cannot be located or when complete resection is not possible, medical treatment with phosphate salts or active vitamin D is necessary. One of the most promising emerging treatments for unresectable tumours that cause TIO is the anti-FGF23 monoclonal antibody KRN23. The recent identification of a fusion of fibronectin and fibroblast growth factor receptor 1 (FGFR1) as a molecular driver in some tumours not only sheds light on the pathophysiology of TIO but also opens the door to a better understanding of the transcription, translocation, post-translational modification and secretion of FGF23, as well as suggesting approaches to targeted therapy. Further study will reveal if the FGFR1 pathway is also involved in tumours that do not harbour the translocation.
Subscribe to Journal
Get full journal access for 1 year
only $59.00 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Tax calculation will be finalised during checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Folpe, A. L. et al. Most osteomalacia-associated mesenchymal tumors are a single histopathologic entity: an analysis of 32 cases and a comprehensive review of the literature. Am. J. Surg. Pathol. 28, 1–30 (2004). An extensive evaluation of the histological aspects of osteomalacia associated with mesenchymal tumours.
Chong, W. H., Molinolo, A. A., Chen, C. C. & Collins, M. T. Tumor-induced osteomalacia. Endocr. Relat. Cancer 18, R53–R77 (2011). An in-depth review covering various aspects of TIO.
Bielesz, B., Klaushofer, K. & Oberbauer, R. Renal phosphate loss in hereditary and acquired disorders of bone mineralization. Bone 35, 1229–1239 (2004).
Carpenter, T. O. Primary disorders of phosphate metabolism. EndoTexthttps://www.ncbi.nlm.nih.gov/books/NBK279172/ (2014). A general review of phosphate metabolism and related disorders.
Crossen, S. S. et al. Tumor-induced osteomalacia in a 3-year-old with unresectable central giant cell lesions. J. Pediatr. Hematol. Oncol. 39, e21–e24 (2017).
Imel, E. A. et al. Sensitivity of fibroblast growth factor 23 measurements in tumor-induced osteomalacia. J. Clin. Endocrinol. Metab. 91, 2055–2061 (2006).
Jiang, Y. et al. Tumor-induced osteomalacia: an important cause of adult-onset hypophosphatemic osteomalacia in China: report of 39 cases and review of the literature. J. Bone Miner. Res. 27, 1967–1975 (2012).
Endo, I. et al. Nationwide survey of fibroblast growth factor 23 (FGF23)-related hypophosphatemic diseases in Japan: prevalence, biochemical data and treatment. Endocr. J. 62, 811–816 (2015).
Evans, D. J. & Azzopardi, J. G. Distinctive tumours of bone and soft tissue causing acquired vitamin-D-resistant osteomalacia. Lancet 1, 353–354 (1972).
Weidner, N. & Santa Cruz, D. Phosphaturic mesenchymal tumors. A polymorphous group causing osteomalacia or rickets. Cancer 59, 1442–1454 (1987).
Sahoo, J. et al. Tumor(s) induced osteomalacia — a curious case of double trouble. J. Clin. Endocrinol. Metab. 99, 395–398 (2014).
Higley, M., Beckett, B., Schmahmann, S., Dacey, E. & Foss, E. Locally aggressive and multifocal phosphaturic mesenchymal tumors: two unusual cases of tumor-induced osteomalacia. Skeletal Radiol. 44, 1825–1831 (2015).
Annamalai, A. K. et al. Needle(s) in the haystack — synchronous multifocal tumor-induced osteomalacia. J. Clin. Endocrinol. Metab. 101, 390–393 (2016).
Leaf, D. E., Pereira, R. C., Bazari, H. & Juppner, H. Oncogenic osteomalacia due to FGF23-expressing colon adenocarcinoma. J. Clin. Endocrinol. Metab. 98, 887–891 (2013).
Lyles, K. W., Berry, W. R., Haussler, M., Harrelson, J. M. & Drezner, M. K. Hypophosphatemic osteomalacia: association with prostatic carcinoma. Ann. Intern. Med. 93, 275–278 (1980).
Mak, M. P. et al. Advanced prostate cancer as a cause of oncogenic osteomalacia: an underdiagnosed condition. Support. Care Cancer 20, 2195–2197 (2012).
Lim, Y. H. et al. Multilineage somatic activating mutations in HRAS and NRAS cause mosaic cutaneous and skeletal lesions, elevated FGF23 and hypophosphatemia. Hum. Mol. Genet. 23, 397–407 (2014).
Ovejero, D. & Collins, M. T. RAS in FGF23: another piece in the puzzle. J. Clin. Endocrinol. Metab. 99, 63–66 (2014).
Lim, Y. H. et al. Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy. J. Am. Acad. Dermatol. 75, 420–427 (2016).
Ovejero, D. et al. Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment. Osteoporos. Int. 27, 3615–3626 (2016). An in-depth review of the cutaneous skeletal hypophosphataemia syndrome.
Carter, J. M., Caron, B. L., Dogan, A. & Folpe, A. L. A novel chromogenic in situ hybridization assay for FGF23 mRNA in phosphaturic mesenchymal tumors. Am. J. Surg. Pathol. 39, 75–83 (2015).
Rowe, P. S. et al. MEPE has the properties of an osteoblastic phosphatonin and minhibin. Bone 34, 303–319 (2004).
Carpenter, T. O. et al. Fibroblast growth factor 7: an inhibitor of phosphate transport derived from oncogenic osteomalacia-causing tumors. J. Clin. Endocrinol. Metab. 90, 1012–1020 (2005).
Berndt, T. et al. Secreted frizzled-related protein 4 is a potent tumor-derived phosphaturic agent. J. Clin. Invest. 112, 785–794 (2003).
De Beur, S. M. et al. Tumors associated with oncogenic osteomalacia express genes important in bone and mineral metabolism. J. Bone Miner. Res. 17, 1102–1110 (2002).
Habra, M. A. et al. Expression analysis of fibroblast growth factor-23, matrix extracellular phosphoglycoprotein, secreted frizzled-related protein-4, and fibroblast growth factor-7: identification of fibroblast growth factor-23 and matrix extracellular phosphoglycoprotein as major factors involved in tumor-induced osteomalacia. Endocr. Pract. 14, 1108–1114 (2008).
Imanishi, Y. et al. Matrix extracellular phosphoglycoprotein is expressed in causative tumors of oncogenic osteomalacia. J. Bone Miner. Metab. 30, 93–99 (2012).
Riminucci, M. et al. FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J. Clin. Invest. 112, 683–692 (2003). A seminal paper showing that FGF23 is produced by fibrous dysplasia tissue.
Sitara, D. et al. Homozygous ablation of fibroblast growth factor-23 results in hyperphosphatemia and impaired skeletogenesis, and reverses hypophosphatemia in Phex-deficient mice. Matrix Biol. 23, 421–432 (2004).
Mirams, M., Robinson, B. G., Mason, R. S. & Nelson, A. E. Bone as a source of FGF23: regulation by phosphate? Bone 35, 1192–1199 (2004).
Lee, J. C. et al. Identification of a novel FN1–FGFR1 genetic fusion as a frequent event in phosphaturic mesenchymal tumour. J. Pathol. 235, 539–545 (2015).
Lee, J. C. et al. Characterization of FN1–FGFR1 and novel FN1–FGF1 fusion genes in a large series of phosphaturic mesenchymal tumors. Mod. Pathol. 29, 1335–1346 (2016). A paper that demonstrates the central role of the FGF1–FGFR1 signalling pathway.
Tanner, Y. & Grose, R. P. Dysregulated FGF signalling in neoplastic disorders. Semin. Cell Dev. Biol. 53, 126–135 (2016).
Cheng, W., Wang, M., Tian, X. & Zhang, X. An overview of the binding models of FGFR tyrosine kinases in complex with small molecule inhibitors. Eur. J. Med. Chem. 126, 476–490 (2017).
Wohrle, S. et al. Pharmacological inhibition of fibroblast growth factor (FGF) receptor signaling ameliorates FGF23-mediated hypophosphatemic rickets. J. Bone Miner. Res. 28, 899–911 (2013).
Imel, E. A. & Peacock, M. X-linked hypophosphatemia: understanding and management. Drugs Future 35, 755–763 (2010).
Lederer, E. Regulation of serum phosphate. J. Physiol. 592, 3985–3995 (2014).
Fukumoto, S. The role of bone in phosphate metabolism. Mol. Cell. Endocrinol. 310, 63–70 (2009).
Shimada, T. et al. FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis. J. Bone Miner. Res. 19, 429–435 (2004).
Murer, H. et al. Renal brush border membrane Na/Pi-cotransport: molecular aspects in PTH-dependent and dietary regulation. Kidney Int. 49, 1769–1773 (1996).
Blau, J. E. & Collins, M. T. The PTH–vitamin D–FGF23 axis. Rev. Endocr. Metab. Disord. 16, 165–174 (2015).
Peacock, M., Heyburn, P. J. & Aaron, J. E. Vitamin D resistant hypophosphataemic osteomalacia: treatment with 1α-hydroxyvitamin D3 . Clin. Endocrinol. (Oxf.) 7, 231s–237s (1977).
Kido, S., Kaneko, I., Tatsumi, S., Segawa, H. & Miyamoto, K. Vitamin D and type II sodium-dependent phosphate cotransporters. Contrib. Nephrol. 180, 86–97 (2013).
DeLuca, H. F. The metabolism and functions of vitamin D. Adv. Exp. Med. Biol. 196, 361–375 (1986).
Sabbagh, Y. Phosphate as a sensor and signaling molecule. Clin. Nephrol. 79, 57–65 (2013).
Bergwitz, C. & Juppner, H. Phosphate sensing. Adv. Chronic Kidney Dis. 18, 132–144 (2011).
Ben-Dov, I. Z. et al. The parathyroid is a target organ for FGF23 in rats. J. Clin. Invest. 117, 4003–4008 (2007).
Jaaskelainen, T., Huhtakangas, J. & Maenpaa, P. H. Negative regulation of human parathyroid hormone gene promoter by vitamin D3 through nuclear factor Y. Biochem. Biophys. Res. Commun. 328, 831–837 (2005).
Rhee, Y. et al. Parathyroid hormone receptor signaling in osteocytes increases the expression of fibroblast growth factor-23 in vitro and in vivo. Bone 49, 636–643 (2011).
Geller, J. L. et al. Cinacalcet in the management of tumor-induced osteomalacia. J. Bone Miner. Res. 22, 931–937 (2007).
Institute of Medicine. Dietary Reference Intakes for Calcium, Phosphorus, Magnesium, Vitamin D, and Fluoride (National Academies Press, 1997).
Yates, A. A., Schlicker, S. A. & Suitor, C. W. Dietary reference intakes: the new basis for recommendations for calcium and related nutrients, B vitamins, and choline. J. Am. Diet Assoc. 98, 699–706 (1998).
Fleet, J. C. & Peacock, M. in The Physiological Basis of Metabolic Bone Disease (eds Morris, H. A., Anderson, P. H. & Christopher Nordin, B. E. ) 13–40 (CRC Press, 2014).
Sabbagh, Y. et al. Intestinal Npt2b plays a major role in phosphate absorption and homeostasis. J. Am. Soc. Nephrol. 20, 2348–2358 (2009).
Burnett, S. M. et al. Regulation of C-terminal and intact FGF-23 by dietary phosphate in men and women. J. Bone Miner. Res. 21, 1187–1196 (2006).
Berndt, T. et al. Evidence for a signaling axis by which intestinal phosphate rapidly modulates renal phosphate reabsorption. Proc. Natl Acad. Sci. USA 104, 11085–11090 (2007).
Labonte, E. D. et al. Gastrointestinal inhibition of sodium–hydrogen exchanger 3 reduces phosphorus absorption and protects against vascular calcification in CKD. J. Am. Soc. Nephrol. 26, 1138–1149 (2015).
Block, G. A. et al. Effect of tenapanor on serum phosphate in patients receiving hemodialysis. J. Am. Soc. Nephrol. 28, 1933–1942 (2017).
Marks, J. et al. Intestinal phosphate absorption and the effect of vitamin D: a comparison of rats with mice. Exp. Physiol. 91, 531–537 (2006).
Capuano, P. et al. Intestinal and renal adaptation to a low-Pi diet of type II NaPi cotransporters in vitamin D receptor- and 1αOHase-deficient mice. Am. J. Physiol. Cell Physiol. 288, C429–C434 (2005).
Peacock, M., Aaron, J. E., Walker, G. S. & Davison, A. M. Bone disease and hyperparathyroidism in chronic renal failure: the effect of 1α-hydroxyvitamin D3 . Clin. Endocrinol. (Oxf.) 7, 73s–81s (1977).
Davis, G. R. et al. Absorption of phosphate in the jejunum of patients with chronic renal failure before and after correction of vitamin D deficiency. Gastroenterology 85, 908–916 (1983).
Xu, H., Inouye, M., Hines, E. R., Collins, J. F. & Ghishan, F. K. Transcriptional regulation of the human NaPi-IIb cotransporter by EGF in Caco-2 cells involves c-myb. Am. J. Physiol. Cell Physiol. 284, C1262–C1271 (2003).
Khuituan, P. et al. Fibroblast growth factor-23 abolishes 1,25-dihydroxyvitamin D3-enhanced duodenal calcium transport in male mice. Am. J. Physiol. Endocrinol. Metab. 302, E903–E913 (2012).
Corut, A. et al. Mutations in SLC34A2 cause pulmonary alveolar microlithiasis and are possibly associated with testicular microlithiasis. Am. J. Hum. Genet. 79, 650–656 (2006).
Stokman, L. et al. A case of pulmonary alveolar microlithiasis associated with a homozygous 195 kb deletion encompassing the entire SLC34A2 gene. Clin. Case Rep. 4, 412–415 (2016).
Tiosano, D. & Hochberg, Z. Hypophosphatemia: the common denominator of all rickets. J. Bone Miner. Metab. 27, 392–401 (2009).
Munns, C. F. et al. Global consensus recommendations on prevention and management of nutritional rickets. J. Clin. Endocrinol. Metab. 101, 394–415 (2016).
Kazama, J. J. Oral phosphate binders: history and prospects. Bone 45 (Suppl. 1), S8–S12 (2009).
Pivnick, E. K., Kerr, N. C., Kaufman, R. A., Jones, D. P. & Chesney, R. W. Rickets secondary to phosphate depletion. A sequela of antacid use in infancy. Clin. Pediatr. (Phila.) 34, 73–78 (1995).
Peacock, M. in The Parathyroids 3rd edn (eds Bilezikian, J. P. et al.) 455–467 (2015). An extensive review on the role of the kidney in regulating mineral metabolism.
Miyamoto, K. et al. Sodium-dependent phosphate cotransporters: lessons from gene knockout and mutation studies. J. Pharm. Sci. 100, 3719–3730 (2011).
Walton, R. J. & Bijvoet, O. L. Nomogram for derivation of renal threshold phosphate concentration. Lancet 2, 309–310 (1975).
Shimada, T. et al. Cloning and characterization of FGF23 as a causative factor of tumor-induced osteomalacia. Proc. Natl Acad. Sci. USA 98, 6500–6505 (2001).
Karim, Z. et al. NHERF1 mutations and responsiveness of renal parathyroid hormone. N. Engl. J. Med. 359, 1128–1135 (2008).
Ansermet, C. et al. Renal Fanconi syndrome and hypophosphatemic rickets in the absence of xenotropic and polytropic retroviral receptor in the nephron. J. Am. Soc. Nephrol. 28, 1073–1078 (2017).
Wang, H. et al. Overexpression of fibroblast growth factor 23 suppresses osteoblast differentiation and matrix mineralization in vitro. J. Bone Miner. Res. 23, 939–948 (2008).
Wallimann, T., Tokarska-Schlattner, M. & Schlattner, U. The creatine kinase system and pleiotropic effects of creatine. Amino Acids 40, 1271–1296 (2011).
Argov, Z., Lofberg, M. & Arnold, D. L. Insights into muscle diseases gained by phosphorus magnetic resonance spectroscopy. Muscle Nerve 23, 1316–1334 (2000).
Kemp, G. J., Meyerspeer, M. & Moser, E. Absolute quantification of phosphorus metabolite concentrations in human muscle in vivo by 31P MRS: a quantitative review. NMR Biomed. 20, 555–565 (2007).
Pesta, D. H. et al. Hypophosphatemia promotes lower rates of muscle ATP synthesis. FASEB J. 30, 3378–3387 (2016).
MacDonald, R. Red cell 2,3-diphosphoglycerate and oxygen affinity. Anaesthesia 32, 544–553 (1977).
Kavanaugh, M. P. & Kabat, D. Identification and characterization of a widely expressed phosphate transporter/retrovirus receptor family. Kidney Int. 49, 959–963 (1996).
McCance, R. A. Osteomalacia with Looser's nodes (Milkman's syndrome) due to a raised resistance to vitamin D acquired about the age of 15 years. Q. J. Med. 16, 33–46 (1947).
Peacock, M. in Metabolic Bone and Stone Disease 3rd edn (eds Nordin, B. E. C., Need, A. G. & Morris, H. A. ) 83–118 (Churchill Livingstone, 1993).
Wang, Y. & DeLuca, H. F. Is the vitamin D receptor found in muscle? Endocrinology 152, 354–363 (2011).
Piemonte, S. et al. Six-year follow-up of a characteristic osteolytic lesion in a patient with tumor-induced osteomalacia. Eur. J. Endocrinol. 170, K1–K4 (2014).
Jan de Beur, S. M. Tumor-induced osteomalacia. JAMA 294, 1260–1267 (2005).
Leow, M. K. et al. Oncogenic osteomalacia presenting as a crippling illness in a young man. Lancet 384, 1236 (2014).
Ogose, A. et al. Recurrent malignant variant of phosphaturic mesenchymal tumor with oncogenic osteomalacia. Skeletal Radiol. 30, 99–103 (2001).
Morimoto, T. et al. Malignant phosphaturic mesenchymal tumor of the pelvis: a report of two cases. Oncol. Lett. 8, 67–71 (2014).
Kruse, K., Kracht, U. & Gopfert, G. Renal threshold phosphate concentration (TmPO4/GFR). Arch. Dis. Child. 57, 217–223 (1982).
Liu, S. & Quarles, L. D. How fibroblast growth factor 23 works. J. Am. Soc. Nephrol. 18, 1637–1647 (2007).
Solano, A., Lew, S. Q. & Ing, T. S. Dent–Wrong disease and other rare causes of the Fanconi syndrome. Clin. Kidney J. 7, 344–347 (2014).
Klootwijk, E. D. et al. Renal Fanconi syndrome: taking a proximal look at the nephron. Nephrol. Dial. Transplant. 30, 1456–1460 (2015).
Kumar, R., Folpe, A. L. & Mullan, B. P. Tumor-induced osteomalacia. Transl Endocrinol. Metab. 7, 1871 (2015).
El-Maouche, D. et al. Stability and degradation of fibroblast growth factor 23 (FGF23): the effect of time and temperature and assay type. Osteoporos. Int. 27, 2345–2353 (2016).
Goetz, R. et al. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23–FGFR–Klotho complex formation. Proc. Natl Acad. Sci. USA 107, 407–412 (2010).
Bhattacharyya, N., Chong, W. H., Gafni, R. I. & Collins, M. T. Fibroblast growth factor 23: state of the field and future directions. Trends Endocrinol. Metab. 23, 610–618 (2012).
Imel, E. A. et al. Iron modifies plasma FGF23 differently in autosomal dominant hypophosphatemic rickets and healthy humans. J. Clin. Endocrinol. Metab. 96, 3541–3549 (2011).
Houang, M. et al. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A). Hum. Pathol. 44, 2711–2718 (2013).
Ishii, A. et al. The levels of somatostatin receptors in causative tumors of oncogenic osteomalacia are insufficient for their agonist to normalize serum phosphate levels. Calcif. Tissue Int. 86, 455–462 (2010).
Jan de Beur, S. M. et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 359, 761–763 (2002).
Chong, W. H. et al. Tumor localization and biochemical response to cure in tumor-induced osteomalacia. J. Bone Miner. Res. 28, 1386–1398 (2013). An important paper that addresses the problem of tumour localization.
Clifton-Bligh, R. J. et al. Improving diagnosis of tumor-induced osteomalacia with Gallium-68 DOTATATE PET/CT. J. Clin. Endocrinol. Metab. 98, 687–694 (2013).
Reubi, J. C. et al. Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur. J. Nucl. Med. 27, 273–282 (2000).
El-Maouche, D. et al. 68Ga-DOTATATE for tumor localization in tumor-induced osteomalacia. J. Clin. Endocrinol. Metab. 101, 3575–3581 (2016).
Ferraz, M. P. et al. Concordance between whole-body scintigraphy 111In-octreotide and 99mTc-sestamibi uptake in the detection of four tumor-induced osteomalacia cases. J. Clin. Endocrinol. Metab. 99, 699–700 (2014).
Nakanishi, K. et al. Whole-body MR imaging in detecting phosphaturic mesenchymal tumor (PMT) in tumor-induced hypophosphatemic osteomalacia. Magn. Reson. Med. Sci. 12, 47–52 (2013).
Chakraborty, P. P., Bhattacharjee, R., Mukhopadhyay, S. & Chowdhury, S. ‘Rachitic rosary sign’ and ‘tie sign’ of the sternum in tumour-induced osteomalacia. BMJ Case Rep.http://dx.doi.org/10.1136/bcr-2016-214766 (2016).
Andreopoulou, P. et al. Selective venous catheterization for the localization of phosphaturic mesenchymal tumors. J. Bone Miner. Res. 26, 1295–1302 (2011).
Takeuchi, Y. et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J. Clin. Endocrinol. Metab. 89, 3979–3982 (2004).
van Boekel, G. et al. Tumor producing fibroblast growth factor 23 localized by two-staged venous sampling. Eur. J. Endocrinol. 158, 431–437 (2008).
Sciubba, D. M. et al. En bloc spondylectomy for treatment of tumor-induced osteomalacia. J. Neurosurg. Spine 11, 600–604 (2009).
Wagner, C. A., Rubio-Aliaga, I., Biber, J. & Hernando, N. Genetic diseases of renal phosphate handling. Nephrol. Dial. Transplant. 29 (Suppl. 4), iv45–iv54 (2014).
Lee, J. Y. & Imel, E. A. The changing face of hypophosphatemic disorders in the FGF-23 era. Pediatr. Endocrinol. Rev. 10 (Suppl. 2), 367–379 (2013).
Clunie, G. P., Fox, P. E. & Stamp, T. C. Four cases of acquired hypophosphataemic (‘oncogenic’) osteomalacia. Problems of diagnosis, treatment and long-term management. Rheumatology (Oxford) 39, 1415–1421 (2000).
Uramoto, N., Furukawa, M. & Yoshizaki, T. Malignant phosphaturic mesenchymal tumor, mixed connective tissue variant of the tongue. Auris Nasus Larynx 36, 104–105 (2009).
Yu, W. J., He, J. W., Fu, W. Z., Wang, C. & Zhang, Z. L. Reports of 17 Chinese patients with tumor-induced osteomalacia. J. Bone Miner. Metab. 35, 298–307 (2017).
Harvey, J. N., Gray, C. & Belchetz, P. E. Oncogenous osteomalacia and malignancy. Clin. Endocrinol. (Oxf.) 37, 379–382 (1992).
Sun, Z. J., Jin, J., Qiu, G. X., Gao, P. & Liu, Y. Surgical treatment of tumor-induced osteomalacia: a retrospective review of 40 cases with extremity tumors. BMC Musculoskelet. Disord. 16, 43 (2015).
Dadoniene, J. et al. Tumour-induced osteomalacia: a literature review and a case report. World J. Surg. Oncol. 14, 4 (2016).
Hautmann, A. H., Hautmann, M. G., Kolbl, O., Herr, W. & Fleck, M. Tumor-induced osteomalacia: an up-to-date review. Curr. Rheumatol. Rep. 17, 512 (2015).
Ruka, W. et al. The megavoltage radiation therapy in treatment of patients with advanced or difficult giant cell tumors of bone. Int. J. Radiat. Oncol. Biol. Phys. 78, 494–498 (2010).
Caudell, J. J. et al. Radiotherapy in the management of giant cell tumor of bone. Int. J. Radiat. Oncol. Biol. Phys. 57, 158–165 (2003).
Tutton, S., Olson, E., King, D. & Shaker, J. L. Successful treatment of tumor-induced osteomalacia with CT-guided percutaneous ethanol and cryoablation. J. Clin. Endocrinol. Metab. 97, 3421–3425 (2012).
Hesse, E., Rosenthal, H. & Bastian, L. Radiofrequency ablation of a tumor causing oncogenic osteomalacia. N. Engl. J. Med. 357, 422–424 (2007).
Paglia, F., Dionisi, S. & Minisola, S. Octreotide for tumor-induced osteomalacia. N. Engl. J. Med. 346, 1748–1749 (2002).
Seufert, J. et al. Octreotide therapy for tumor-induced osteomalacia. N. Engl. J. Med. 345, 1883–1888 (2001).
Khosravi, A. et al. Determination of the elimination half-life of fibroblast growth factor-23. J. Clin. Endocrinol. Metab. 92, 2374–2377 (2007).
Zimering, M. B., Caldarella, F. A., White, K. E. & Econs, M. J. Persistent tumor-induced osteomalacia confirmed by elevated postoperative levels of serum fibroblast growth factor-23 and 5-year follow-up of bone density changes. Endocr. Pract. 11, 108–114 (2005).
Bhambri, R. et al. Changes in bone mineral density following treatment of osteomalacia. J. Clin. Densitom. 9, 120–127 (2006).
Collins, M. T. et al. Striking response of tumor-induced osteomalacia to the FGFR inhibitor NVP-BGJ398. Annual Meeting of the American Society for Bone and Mineral Research SA0035 (2015).
Zhang, M. Y. et al. Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice. Endocrinology 153, 1806–1816 (2012).
Carpenter, T. O. et al. Effects of KRN23, an anti-FGF23 antibody, in patients with tumor induced osteomalacia and epidermal nevus syndrome: results from an ongoing phase 2 study. Annual Meeting of the American Society for Bone and Mineral Research 1098 (2016).
Aono, Y. et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J. Bone Miner. Res. 24, 1879–1888 (2009).
Carpenter, T. O. et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J. Clin. Invest. 124, 1587–1597 (2014). A study that shows the effect of pharmacological treatment in patients with X-linked hypophosphataemia.
Imel, E. A. et al. Prolonged correction of serum phosphorus in adults with X-linked hypophosphatemia using monthly doses of KRN23. J. Clin. Endocrinol. Metab. 100, 2565–2573 (2015).
Zhang, X. et al. Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) in the first multiple ascending-dose trial treating adults with X-linked hypophosphatemia. J. Clin. Pharmacol. 56, 176–185 (2016).
Fukumoto, S. FGF23–FGF receptor/klotho pathway as a new drug target for disorders of bone and mineral metabolism. Calcif. Tissue Int. 98, 334–340 (2016). An extensive review that discusses the potential of the FGF23–FGFR–KLOTHO complex as a therapeutic target.
Wolf, M. & White, K. E. Coupling fibroblast growth factor 23 production and cleavage: iron deficiency, rickets, and kidney disease. Curr. Opin. Nephrol. Hypertens. 23, 411–419 (2014).
Wolf, M., Koch, T. A. & Bregman, D. B. Effects of iron deficiency anemia and its treatment on fibroblast growth factor 23 and phosphate homeostasis in women. J. Bone Miner. Res. 28, 1793–1803 (2013).
Bishay, R. H., Ganda, K. & Seibel, M. J. Long-term iron polymaltose infusions associated with hypophosphataemic osteomalacia: a report of two cases and review of the literature. Ther. Adv. Endocrinol. Metab. 8, 14–19 (2017).
Hediger, M. A., Clemencon, B., Burrier, R. E. & Bruford, E. A. The ABCs of membrane transporters in health and disease (SLC series): introduction. Mol. Aspects Med. 34, 95–107 (2013).
Reimer, R. J. SLC17: a functionally diverse family of organic anion transporters. Mol. Aspects Med. 34, 350–359 (2013).
Forster, I. C., Hernando, N., Biber, J. & Murer, H. Phosphate transporters of the SLC20 and SLC34 families. Mol. Aspects Med. 34, 386–395 (2013).
Biber, J., Hernando, N. & Forster, I. Phosphate transporters and their function. Annu. Rev. Physiol. 75, 535–550 (2013).
Albano, G. et al. Sodium-dependent phosphate transporters in osteoclast differentiation and function. PLoS ONE 10, e0125104 (2015).
Zoidis, E., Ghirlanda-Keller, C., Gosteli-Peter, M., Zapf, J. & Schmid, C. Regulation of phosphate (Pi) transport and NaPi-III transporter (Pit-1) mRNA in rat osteoblasts. J. Endocrinol. 181, 531–540 (2004).
Cowan, C. M. et al. NELL-1 increases pre-osteoblast mineralization using both phosphate transporter Pit1 and Pit2. Biochem. Biophys. Res. Commun. 422, 351–357 (2012).
Wang, L., Nancollas, G. H., Henneman, Z. J., Klein, E. & Weiner, S. Nanosized particles in bone and dissolution insensitivity of bone mineral. Biointerphases 1, 106–111 (2006).
The authors thank J. Berglund (NIH, Bethesda, Maryland, USA) for the image used in Figure 3b.
S.M. has served as speaker for Abiogen, Amgen, Diasorin, Eli Lilly, Italfarmaco, Fujii, Merck Sharp & Dohme and Takeda. He has also served on the advisory boards of Amgen and Eli Lilly. All other authors declare no competing interests.
About this article
Cite this article
Minisola, S., Peacock, M., Fukumoto, S. et al. Tumour-induced osteomalacia. Nat Rev Dis Primers 3, 17044 (2017). https://doi.org/10.1038/nrdp.2017.44
Nature Reviews Endocrinology (2021)
European Radiology (2021)
Calcified Tissue International (2021)
Calcified Tissue International (2021)
Virchows Archiv (2021)